Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
IPO Year: 2000
Exchange: NASDAQ
Website: exelixis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | $36.00 → $40.00 | Outperform → Market Perform | BMO Capital Markets |
| 12/17/2024 | $35.00 → $39.00 | Buy → Neutral | BofA Securities |
| 10/16/2024 | $30.00 → $34.00 | Outperform | RBC Capital Mkts |
| 9/19/2024 | $30.00 | Neutral | UBS |
| 4/11/2024 | $25.00 | Overweight → Equal Weight | Barclays |
| 12/19/2023 | $27.00 | Buy | BTIG Research |
| 12/15/2023 | $31.00 | Buy | Citigroup |
| 9/26/2023 | $28.00 | Buy | H.C. Wainwright |
| 8/22/2023 | $25.00 → $29.00 | Outperform | Oppenheimer |
| 8/8/2023 | $18.00 | Market Perform | SVB Securities |
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
– Cabozantinib franchise achieves approximately $1.805 billion in preliminary U.S. net product revenues for fiscal year 2024 – – Fiscal year 2025 net product revenues guidance of $1.95 billion - $2.05 billion – – Presentation and webcast at 43rd Annual J.P. Morgan Healthcare Conference tomorrow, Monday, January 13th at 5:15 p.m. PT / 8:15 p.m. ET – Exelixis, Inc. (NASDAQ:EXEL) today announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for fiscal year 2025 and delivered an update on its business. Exelixis anticipates 2025 will be a year of clinical and regulatory execution and continued growth for its cabozantinib franchise, as wel
Exelixis, Inc. (NASDAQ:EXEL) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic (epNET) will no longer be the subject of discussion at an Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration by FDA with a Prescription Drug User Fee Act action date of April 3, 2025. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by
– Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. PT / 8:15 p.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by
ROTTERDAM, The Netherlands, Dec. 17, 2024 /PRNewswire/ -- Sairopa B.V., today announced it has achieved a milestone event in its exclusive clinical development and option agreement with Exelixis, Inc. (NASDAQ:EXEL) involving ADU-1805, an innovative anti-SIRPα antibody with the potential to enhance the immune system's ability to combat cancer. Under the terms of the agreement, Exelixis has an exclusive option to license worldwide development and commercialization rights for ADU-1805 and other anti-SIRPα antibodies following the review of data from Sairopa's phase 1 clinical studies. As part of its collaboration with Exelixis, Sairopa has previously received from Exelixis an upfront payment o
-- Presentations to be webcast on www.exelixis.com -- Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in December: Piper Sandler 36th Annual Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, December 3 in New York City. Citi 2024 Global Healthcare Conference: Exelixis is scheduled to present at 1:45 p.m. ET / 10:45 a.m. PT on Wednesday, December 4 in Miami. To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for
Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. The sNDA is based on the final results of the phase 3 CABINET pivotal trial, conducted by the National Cancer Institute's National Clinical Trials Network, evaluating cabozantinib compared with placebo in advanced pNET and advanced epNET. In August 2024, Exelixis anno
- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim's Inaugural Healthcare Innovation Conference: Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, November 12 in Boston. Stifel 2024 Healthcare Conference: Exelixis is scheduled to present at 10:20 a.m. ET / 7:20 a.m. PT on Monday, November 18 in New York City. Jefferies London Healthcare Conference: Exelixis is scheduled to present at 10:30 a.m. BST / 5:30 a.m. ET / 2:30 a.m. PT on Tuesday, November 19 in London, UK. To access the webcast link
- Total Revenues of $539.5 million, Cabozantinib Franchise U.S. Net Product Revenues of $478.1 million - - GAAP Diluted EPS of $0.40, Non-GAAP Diluted EPS of $0.47 - - Increasing Total Revenues and Net Product Revenues Guidance - - Favorable Ruling on Cabozantinib Patent Litigation Received from U.S. District Court - - Collaboration with Merck Expands Zanzalintinib Development Program - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2024 financial results will be released on Tuesday, October 29, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Ev
Exelixis, Inc. (NASDAQ:EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. District Court for the District of Delaware ruled in Exelixis' favor, rejecting MSN's challenge to three Orange Book-listed patents related to cabozantinib, including U.S. Patents No. 11,091,439 (crystalline salt); 11,091,440 (pharmaceutical compositions); and 11,098,015 (methods of treatment). The District Court's decision in Exelixis' favor on the validity of these patents follows an earlier Stipulation entered on June 21, 2022, that MSN's proposed generic cabozantinib product (Abbreviated New Drug
8-K - EXELIXIS, INC. (0000939767) (Filer)
10-Q - EXELIXIS, INC. (0000939767) (Filer)
8-K - EXELIXIS, INC. (0000939767) (Filer)
8-K - EXELIXIS, INC. (0000939767) (Filer)
8-K - EXELIXIS, INC. (0000939767) (Filer)
S-8 - EXELIXIS, INC. (0000939767) (Filer)
10-Q - EXELIXIS, INC. (0000939767) (Filer)
8-K - EXELIXIS, INC. (0000939767) (Filer)
8-K - EXELIXIS, INC. (0000939767) (Filer)
8-K - EXELIXIS, INC. (0000939767) (Filer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
BMO Capital Markets downgraded Exelixis from Outperform to Market Perform and set a new price target of $40.00 from $36.00 previously
BofA Securities downgraded Exelixis from Buy to Neutral and set a new price target of $39.00 from $35.00 previously
RBC Capital Mkts reiterated coverage of Exelixis with a rating of Outperform and set a new price target of $34.00 from $30.00 previously
UBS initiated coverage of Exelixis with a rating of Neutral and set a new price target of $30.00
Barclays downgraded Exelixis from Overweight to Equal Weight and set a new price target of $25.00
BTIG Research initiated coverage of Exelixis with a rating of Buy and set a new price target of $27.00
Citigroup initiated coverage of Exelixis with a rating of Buy and set a new price target of $31.00
H.C. Wainwright initiated coverage of Exelixis with a rating of Buy and set a new price target of $28.00
Oppenheimer reiterated coverage of Exelixis with a rating of Outperform and set a new price target of $29.00 from $25.00 previously
SVB Securities initiated coverage of Exelixis with a rating of Market Perform and set a new price target of $18.00
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-16) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 208692, Application Classification: Labeling
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-14) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 07/14/2022. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-12) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/17/2021. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-10) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 01/22/2021. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy
SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)
SC 13G - EXELIXIS, INC. (0000939767) (Subject)
SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)
SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)
SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)
SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)
SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)
SC 13D - EXELIXIS, INC. (0000939767) (Subject)
SC 13D - EXELIXIS, INC. (0000939767) (Subject)
SC 13G/A - EXELIXIS, INC. (0000939767) (Subject)
TORONTO, Oct. 9, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE:AIAI) (OTCQB:AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, is pleased to announce the appointment of P.J. Haley, Executive Vice President, Commercial at Exelixis, Inc. (NASDAQ:EXEL), as a director of the Company, effective October 15th, 2024. Mr. Haley will be replacing Sheetal Jaitly, who is stepping down as a director after a period of dedicated service and contributions to the Company. As NetraMark focuses on advancing its technology for late phas
– Cabozantinib franchise achieves approximately $1.630 billion in preliminary U.S. net product revenues for fiscal year 2023 – – Fiscal year 2024 net product revenues guidance of $1,650 million - $1,750 million; 2024 R&D expense guidance of $925 million - $975 million – – Appointment of two new board members, Mary C. Beckerle, Ph.D., and Gail Eckhardt, M.D., with extensive drug development and corporate governance expertise – – Implementing corporate restructuring to focus R&D resources on clinical stage and IND-enabling activities to maximize pipeline success and operational efficiency – – Board of Directors authorized $450 million share repurchase in 2024 after successful completi
-- Dr. Peterson's extensive experience includes clinical development, medical affairs, and regulatory leadership in support of innovative oncology product portfolios -- Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer. Dr. Peterson is a veteran oncology drug development leader whose experience includes senior clinical development and operational roles at Genentech, Medivation, BeiGene and CytomX. She joins Exelixis as the company accelerates development of its product pipeline and builds on the success of its global cabozantinib oncology franchise. "With a
Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, today announced the appointment of Julie Anne Smith as Chief Executive Officer (CEO) and member of the Board of Directors. Ms. Smith has over 20 years of experience in the life science industry, with a focus on leading private and public biotech companies through development and commercialization of therapeutics for orphan diseases. Pamela Conley, Ph.D., cofounder and founding CEO of Nuvig Therapeutics, will serve as the Company's Chief Scientific Officer. "The board is very grateful to Pam for leading Nuvig from inception to this exciting inflection po
Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Executive Officer and serve as a member of the Board of Directors starting July 5th, 2022. Current CEO and company co-founder, Kevin Appelbaum, will continue to serve in that role until then. "I'm thrilled to welcome Frank to the Better Therapeutics team," said outgoing CEO Kevin Appelbaum. "Over the past seven years, I have had the privilege of assembling and leading an extraordinarily talented and committed t
FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors. Mr. Karbe, who most recently served as President and Chief Financial Officer of Myovant Sciences, Inc. (NYSE:MYOV), brings over twenty-five years of financial and life-sciences expertise to Phathom. "We are thrilled to welcome Frank to our Board as we approach a critical inflection point for Phathom," said Terrie Curran, President and Chief Executive Officer of Phathom. "Frank's financial, business
Company announces development candidate selection of its second gene therapy program, TN-401, targeting the leading genetic cause of arrhythmogenic right ventricular cardiomyopathy (gARVC) IND applications for TN-201 and TN-301 (previously named TYA-11631) expected to be submitted in the second half of 2022 Appoints Jennifer Drimmer, J.D., as General Counsel Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today provided a 2022 business update including the selection of TN-401 as the development candidate for the treatment of Genetic Arrhythmogenic
– Veteran drug developer's career spans patient care, the FDA and biopharma – – Dr. Goodman will lead Exelixis' expansion to the East Coast – Exelixis, Inc. (NASDAQ:EXEL) today announced the appointment of Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer. Dr. Goodman has more than 20 years of oncology experience as a drug development leader at global biopharmaceutical organizations, regulator and clinician. She joins Exelixis from Merck, where she served as Vice President, Clinical Research and Therapeutic Area Head, Late Stage Oncology; her previous tenures in the biopharmaceutical industry include clinical development
- Total Revenues of $539.5 million, Cabozantinib Franchise U.S. Net Product Revenues of $478.1 million - - GAAP Diluted EPS of $0.40, Non-GAAP Diluted EPS of $0.47 - - Increasing Total Revenues and Net Product Revenues Guidance - - Favorable Ruling on Cabozantinib Patent Litigation Received from U.S. District Court - - Collaboration with Merck Expands Zanzalintinib Development Program - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2024 financial results will be released on Tuesday, October 29, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Ev
- Total Revenues of $637.2 million, Cabozantinib Franchise U.S. Net Product Revenues of $437.6 million - - GAAP Diluted EPS of $0.77, Non-GAAP Diluted EPS of $0.84 - - U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application (sNDA) for Cabozantinib in Advanced Neuroendocrine Tumors (NET) - - Earned $150 million Cabozantinib Sales-Based Milestone from Ipsen - - Completed $450 million Stock Repurchase Program for 2024 - - Announced Additional Stock Repurchase Program for up to $500 million through the End of 2025 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the second quarter of 20
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the E
- Total Revenues of $425 million, Cabozantinib Franchise U.S. Net Product Revenues of $379 million - - Restructuring Expenses of $32.8 million Recorded - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.17 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones. "In the first quarter of 2024, Exelixis made important progress to advance a diverse, multi-product portfolio of small molecules and biotherapeutic
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Ev
- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 - - Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the Fiscal Year 2023, including $429 million for the Fourth Quarter of 2023 - - GAAP Diluted EPS of $0.27 for the Fourth Quarter of 2023, $0.65 for the Fiscal Year 2023 - - Non-GAAP Diluted EPS of $0.33 for the Fourth Quarter of 2023, $0.90 for the Fiscal Year 2023 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving key corporat
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and fiscal year 2023 financial results will be released on Tuesday, February 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com an
- Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the third quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. "The third quarter of 2023 was another strong one for the CABOMETYX® commercial franchise, which continues to fuel the buildout of our differentiated pipeline of small molecules and biotherapeutics," said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. "CAB
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2023 financial results will be released on Wednesday, November 1, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to th